iShares, the world’s largest ETF company, is looking to market two U.S. equities ETFs linked to MSCI benchmarks that weight securities based on risk and value measures.
In two separate filings, the company detailed plans for a risk-weighted and a value-weighted ETF that track MSCI benchmarks constructed around the broad, market-capitalization-weighted MSCI USA Index, which comprises securities in the top 85 percentile by market cap.
Plans for such funds is part of a relatively new trend in the worlds of ETFs and indexing centering on “smart beta” or so-called strategy indexes that attempt to carve up the investment universe on the basis of specific factors—in this case, risk and value.
The iShares MSCI USA Risk Weighted Index Fund tracks the MSCI USA Risk Weighted Index, which “reweights” the securities comprised in the broader MSCI USA Index in an effort to have those with the lowest risk profiles represent a larger percentage of the mix.
Risk is measured as historical variance over a three-year period of weekly return data, with those with the lowest variance ranking highest in the portfolio, the filing said. In the end, the methodology is designed to show lower realized volatility relative to the parent MSCI index.
The iShares MSCI USA Value Weighted Index Fund applies the same reweighting concept to the broader MSCI USA Index, but hones in on stocks that show lower market value relative to “certain accounting measures of value,” such as book value, three-year moving average of sales, earnings and cash earnings, the second filing said.
While energy, financials and information technology are the main sectors comprised the value-weighted portfolio, consumer discretionary and staples, financials and utilities companies represent the majority of the risk-weighted ETF.
Both funds would join the iShares MSCI USA Index Fund (NYSEArca: EUSA), which has gathered $155 million since it came to market in mid-2010. EUSA has an annual expense ratio of 0.15 percent.
Neither filing disclosed planned tickers, fees or the exchange where the ETFs will be listed.
It's easy to be blinded by headline numbers. The rally in biotech isn't so simple.
A low-volatility emerging markets ETF outpaces its plain-vanilla counterpart as it marks its three-year anniversary.
It may have been inadvertent, but the SEC’s ruling to block nontransparent active ETFs is a real plus for investors.
Knowing what ‘yield’ even means is a crucial requirement for ETF investors.